Activation of the γ-Aminobutyric Acid Receptor Type B Suppresses the Proliferation of Lung Adenocarcinoma Cells.

IF 1.6 4区 医学 Q4 ONCOLOGY
Yubin Zhou, Kullanat Khawkhiaw, Kanyarat Thithuan, Charupong Saengboonmee
{"title":"Activation of the γ-Aminobutyric Acid Receptor Type B Suppresses the Proliferation of Lung Adenocarcinoma Cells.","authors":"Yubin Zhou, Kullanat Khawkhiaw, Kanyarat Thithuan, Charupong Saengboonmee","doi":"10.21873/anticanres.17533","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The roles of γ-aminobutyric acid (GABA) and its receptors in lung cancer development and progression remain controversial. This study aimed to investigate the effects of activating GABA receptor type B (GABA-B receptor) using baclofen, a GABA-B receptor agonist, on the proliferation of lung adenocarcinoma cells and its underlying mechanisms.</p><p><strong>Materials and methods: </strong>Differential expression of GABA-B receptors was analyzed using the online Gene Expression Profiling Interactive Analysis tool. Lung adenocarcinoma cell lines, A549 and PC-9, were cultured in RPMI-1640 medium and used for <i>in vitro</i> experiments. Effects of baclofen on cancer cell proliferation were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Mechanisms of how baclofen inhibits cell proliferation were determined using flow cytometry and western blots.</p><p><strong>Results: </strong>The expression of GABA-B1 receptor was down-regulated in lung adenocarcinoma compared with normal lung tissues, while GABA-B2 receptor expression was not different between cancer and normal samples. Baclofen significantly inhibited the proliferation of lung adenocarcinoma cells in a dose-dependent manner in both cell lines. Flow cytometry suggested that cancer cells were arrested at the G<sub>1</sub> phase of the cell cycle after being treated with baclofen. Thus, the expression of proteins of the G<sub>1</sub> cell cycle machinery, namely cyclin D1, cyclin E, cyclin-dependent kinase (CDK) 4, and CDK6, were significantly suppressed. The phosphorylation of CDK2 was also suppressed after baclofen treatment. Moreover, baclofen treatment increased phosphorylated glycogen synthase kinase 3 (GSK3) levels, suggesting inhibition of carcinogenic GSK3 signaling pathway in lung adenocarcinoma.</p><p><strong>Conclusion: </strong>GABA-B1 receptors were down-regulated in lung adenocarcinoma cells. Non-specific activation of the GABA-B receptor by baclofen significantly inhibited lung adenocarcinoma cell proliferation by cell cycle arrest and suppressed the GSK3 signaling pathway.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1513-1523"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17533","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: The roles of γ-aminobutyric acid (GABA) and its receptors in lung cancer development and progression remain controversial. This study aimed to investigate the effects of activating GABA receptor type B (GABA-B receptor) using baclofen, a GABA-B receptor agonist, on the proliferation of lung adenocarcinoma cells and its underlying mechanisms.

Materials and methods: Differential expression of GABA-B receptors was analyzed using the online Gene Expression Profiling Interactive Analysis tool. Lung adenocarcinoma cell lines, A549 and PC-9, were cultured in RPMI-1640 medium and used for in vitro experiments. Effects of baclofen on cancer cell proliferation were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Mechanisms of how baclofen inhibits cell proliferation were determined using flow cytometry and western blots.

Results: The expression of GABA-B1 receptor was down-regulated in lung adenocarcinoma compared with normal lung tissues, while GABA-B2 receptor expression was not different between cancer and normal samples. Baclofen significantly inhibited the proliferation of lung adenocarcinoma cells in a dose-dependent manner in both cell lines. Flow cytometry suggested that cancer cells were arrested at the G1 phase of the cell cycle after being treated with baclofen. Thus, the expression of proteins of the G1 cell cycle machinery, namely cyclin D1, cyclin E, cyclin-dependent kinase (CDK) 4, and CDK6, were significantly suppressed. The phosphorylation of CDK2 was also suppressed after baclofen treatment. Moreover, baclofen treatment increased phosphorylated glycogen synthase kinase 3 (GSK3) levels, suggesting inhibition of carcinogenic GSK3 signaling pathway in lung adenocarcinoma.

Conclusion: GABA-B1 receptors were down-regulated in lung adenocarcinoma cells. Non-specific activation of the GABA-B receptor by baclofen significantly inhibited lung adenocarcinoma cell proliferation by cell cycle arrest and suppressed the GSK3 signaling pathway.

γ-氨基丁酸受体B型的激活抑制肺腺癌细胞的增殖。
背景/目的:γ-氨基丁酸(GABA)及其受体在肺癌发生发展中的作用仍有争议。本研究旨在探讨GABA-B受体激动剂巴氯芬激活B型GABA受体(GABA-B受体)对肺腺癌细胞增殖的影响及其机制。材料和方法:使用在线基因表达谱交互分析工具分析GABA-B受体的差异表达。在RPMI-1640培养基中培养肺腺癌细胞A549和PC-9,并进行体外实验。采用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑法测定巴氯芬对癌细胞增殖的影响。利用流式细胞术和western blots检测巴氯芬抑制细胞增殖的机制。结果:肺腺癌组织中GABA-B1受体表达较正常肺组织下调,而GABA-B2受体表达在癌组织与正常肺组织中无差异。巴氯芬在两种细胞系中均以剂量依赖的方式显著抑制肺腺癌细胞的增殖。流式细胞术显示,经巴氯芬治疗后,癌细胞被阻滞在细胞周期的G1期。因此,G1细胞周期机制的蛋白,即cyclin D1、cyclin E、cyclin依赖性激酶(CDK) 4和CDK6的表达被显著抑制。巴氯芬治疗后,CDK2的磷酸化也被抑制。此外,巴氯芬治疗增加了磷酸化糖原合成酶激酶3 (GSK3)水平,表明在肺腺癌中抑制了致癌的GSK3信号通路。结论:GABA-B1受体在肺腺癌细胞中表达下调。巴氯芬非特异性激活GABA-B受体可通过细胞周期阻滞抑制肺腺癌细胞增殖,抑制GSK3信号通路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anticancer research
Anticancer research 医学-肿瘤学
CiteScore
3.70
自引率
10.00%
发文量
566
审稿时长
2 months
期刊介绍: ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信